Donald L. Lamm, MD | Authors

BCG Immunotherapy for Transitional-Cell Carcinoma in Situ of the Bladder

October 01, 1995

Prior to the advent of BCG immunotherapy, bladder carcinoma in situ often progressed to muscle invasion. Intravesical chemotherapy completely eradicates the disease in 50% of patients, but fewer than 20% remain disease free after 5 years. Complete responses have been reported in 70% or more of BCG treated patients, nearly two-thirds of which are durable.